Last reviewed · How we verify
Docetaxel-PM
Docetaxel-PM is a Taxane chemotherapy Small molecule drug developed by Sung Yong Oh. It is currently in Phase 2 development for Non-small cell lung cancer, Breast cancer. Also known as: NANOXEL-M, Nanoxel M.
Docetaxel-PM is a taxane chemotherapy medication that works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells.
Docetaxel-PM is a taxane chemotherapy medication that works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells. Used for Non-small cell lung cancer, Breast cancer.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Docetaxel-PM |
|---|---|
| Also known as | NANOXEL-M, Nanoxel M |
| Sponsor | Sung Yong Oh |
| Drug class | Taxane chemotherapy |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Docetaxel-PM binds to tubulin and promotes the assembly of microtubules, leading to the stabilization of microtubules and the inhibition of cell division. This results in the induction of apoptosis in rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Mucositis
- Alopecia
Key clinical trials
- A Phase I Study of SIM0388 in Participants With Malignant Ascites. (PHASE1)
- Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer (PHASE2)
- A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors (PHASE2)
- Study to Evaluate the Safety of Nanoxel M Inj.
- A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients (PHASE2)
- Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC (PHASE3)
- A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer (PHASE2)
- Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel-PM CI brief — competitive landscape report
- Docetaxel-PM updates RSS · CI watch RSS
- Sung Yong Oh portfolio CI
Frequently asked questions about Docetaxel-PM
What is Docetaxel-PM?
How does Docetaxel-PM work?
What is Docetaxel-PM used for?
Who makes Docetaxel-PM?
Is Docetaxel-PM also known as anything else?
What drug class is Docetaxel-PM in?
What development phase is Docetaxel-PM in?
What are the side effects of Docetaxel-PM?
What does Docetaxel-PM target?
Related
- Drug class: All Taxane chemotherapy drugs
- Target: All drugs targeting Microtubules
- Manufacturer: Sung Yong Oh — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Breast cancer
- Also known as: NANOXEL-M, Nanoxel M
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing